ArticleJournal for immunotherapy of cancer2025

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial.

Jason J Luke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.